Summit Therapeutics stock rises on positive cancer trial data By Investing.com
Summit Therapeutics (NASDAQ:SMMT) shares rose about 3% after updated Phase III HARMONi overall survival results for ivonescimab plus chemotherapy in EGFR-mutated NSCLC. For Western patients, hazard ratio was 0.76 with median follow-up 23.2 months. The updated analysis was submitted to the FDA under its BLA, with a PDUFA goal date of Nov. 14, 2026.
How this was made
The 30-second read
Why it matters
The updated overall survival analysis extends follow-up for Western patients and reports a hazard ratio of 0.76 consistent with Asian patients, and it has been made available to the FDA during ongoing BLA review.
Market read
Traders may reassess regulatory probability and timing premium into the FDA decision window based on longer-maturity OS data and continued acceptable safety.
What to watch
Regulatory impact depends on FDA interpretation of OS maturity, endpoint hierarchy, and whether progression-free survival plus safety is sufficient for approval despite borderline OS significance.
Background
The HARMONi Phase III trial evaluates ivonescimab plus chemotherapy in EGFR-mutated, locally advanced or metastatic non-squamous NSCLC after prior third-generation EGFR TKI treatment.
Ticker impact
Summit Therapeutics shares rose 3% after updated Phase III HARMONi overall survival results for ivonescimab plus chemotherapy, including Western hazard ratio 0.76.
Near-term upside bias versus peers if investors view the OS update as de-risking the BLA, though statistical significance was not achieved in the earlier primary OS readout.
The article provides new OS follow-up metrics (data cut June 2026) and notes the updated analysis was submitted to the FDA, with a defined PDUFA goal date of Nov 14, 2026.
Market effects
Reinforces investor appetite for EGFR-mutated NSCLC immunotherapy-combination programs with OS follow-up updates.
No direct regional market mechanism beyond the Western versus Asian consistency described in the trial.
Global Phase III OS update may affect broader oncology risk perception for similar late-stage programs.
Counterpoint
Despite improved hazard ratios, the earlier primary OS analysis still missed statistical significance (p=0.057), so the market may overreact to hazard ratio optics.
Key entities
- companySummit Therapeutics Inc.
NASDAQ-listed company whose ivonescimab Phase III HARMONi updated OS results were released and submitted to the FDA as part of its BLA review.
- drugivonescimab
Investigational antibody evaluated in combination with chemotherapy in the HARMONi trial.
- regulatorFDA
Regulatory body reviewing Summit’s BLA, with a stated PDUFA goal action date of Nov 14, 2026.
